Canaccord Genuity Reiterates Buy on Oncolytics Biotech, Maintains $5 Price Target
Portfolio Pulse from richadhand@benzinga.com
Canaccord Genuity analyst John Newman reiterates a Buy rating on Oncolytics Biotech (NASDAQ:ONCY) and maintains a $5 price target.
June 23, 2023 | 2:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Canaccord Genuity analyst John Newman reiterates a Buy rating on Oncolytics Biotech (NASDAQ:ONCY) and maintains a $5 price target.
The Buy rating and maintained $5 price target by Canaccord Genuity analyst John Newman indicates a positive outlook for Oncolytics Biotech (NASDAQ:ONCY) in the short term. This reaffirmation of the Buy rating can potentially boost investor confidence and have a positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100